Schrödinger, Inc. (SDGR)
$27.28+3.37%Close
BUYCRISIS · day 3
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.0B
- Beta
- 1.69
- P/E (TTM)
- -39.05
- Short % float
- 17.57%
- Days to cover
- 3.1
- SI change
- -9.3%
- 1W
- -10.00%
- 1M
- +45.11%
- vs SPY 1W
- -11.16%
- vs SPY 1M
- +42.11%
Industry peers
FMP comparable companies · ranked by market cap
- TXGBUY10x Genomics, Inc.$12.4BCRISISQ 12$97.74+4.36%
- ABCLBUYAbCellera Biologics Inc.$4.2BCRISISQ -6$13.78+4.41%
- PGNYBUYProgyny, Inc.$2.0BRECOVERYQ 14$25.86+0.36%
- IMNMSELLImmunome, Inc.$2.0BCRISISQ 18$21.17+1.24%
- AZTABUYAzenta, Inc.$2.0BRECOVERYQ 9$42.73+4.78%
- OMCLBUYOmnicell, Inc.$1.6BRECOVERYQ 6$34.64+2.84%
- OMDABUYOmada Health$1.2BRECOVERYQ 2$20.95+3.51%
- TDOCSELLTeladoc Health, Inc.$1.1BRECOVERYQ -0$5.79+4.15%
- PHRBUYPhreesia, Inc.$641MRECOVERYQ -4$10.37+1.41%
- EVOSELLEvotec SE$590MCRISISQ 16$1.66-2.55%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on SDGR?
- LOPJLB’s latest quantitative signal on Schrödinger, Inc. (SDGR) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is SDGR in?
- Schrödinger, Inc. (SDGR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Schrödinger, Inc. (SDGR) do?
- Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform…